Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.
Researchers use genetic tools to propose a new diagnostic category —
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood. The researchers found the condition surprisingly common in older patients with low blood counts. … Read the full story from the UC San Diego Newsroom
Dr. Bejar was one of 41 UC San Diego Health physicians named on the list of San Diego’s Top Doctors for 2015. The annual list is compiled by the San Diego County Medical Society and San Diego Magazine.